Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer

被引：4
|
作者：
Pujade-Lauraine, Eric [1 ]
机构：
[1] Univ Paris 05, Hop Univ Paris Ctr, Unite Canc Femme & Rech Clin, F-75004 Paris, France
来源：
JOURNAL OF GYNECOLOGIC ONCOLOGY | 2013年 / 24卷 / 03期
关键词：
TRIAL;
D O I：
10.3802/jgo.2013.24.3.209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：209 / 211
页数：3
相关论文
共 50 条
  • [21] Platinum-gemcitabine-bevacizumab (PGA) for platinum-resistant/refractory recurrent ovarian cancer.
    Niu, Jiaxin
    Kundranda, Madappa N.
    Weiss, Glen J.
    Farley, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Treosulfan in platinum-resistant ovarian cancer
    Olesen, Katrine Dam
    Larsen, Anja Tolstrup Raedkjaer
    Jensen, Lars Henrik
    Steffensen, Karina Dahl
    Sondergaard, Stine Rauff
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (07) : 1045 - 1051
  • [23] Immunotherapy for platinum-resistant ovarian cancer
    Bogani, Giorgio
    Lopez, Salvatore
    Mantiero, Mara
    Ducceschi, Monika
    Bosio, Sara
    Ruisi, Simona
    Sarpietro, Giuseppe
    Guerrisi, Rocco
    Brusadelli, Claudia
    Dell'Acqua, Andrea
    Di Donato, Violante
    Raspagliesi, Francesco
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 484 - 488
  • [24] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Cannistra, Stephen A.
    Matulonis, Ursula A.
    Penson, Richard T.
    Hambleton, Julie
    Dupont, Jakob
    Mackey, Howard
    Douglas, Jeffrey
    Burger, Robert A.
    Armstrong, Deborah
    Wenham, Robert
    McGuire, William
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
  • [25] REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
    Lavacchi, Daniele
    Fancelli, Sara
    Michelet, Marta Rita Gatta
    Catalano, Martina
    Roviello, Giandomenico
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 402 - 404
  • [26] Feasibility of bevacizumab combined with gemcitabine in treatment of platinum-resistant epithelial ovarian cancer.
    Kogiku, Ai
    Nagao, Shoji
    Suzuki, Kazuhiro
    Yamamoto, Kasumi
    Senda, Tokihiro
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Sudo, Tamotsu
    Yamaguchi, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer
    Nasu, Hiroki
    Nishio, Shin
    Park, Jongmyung
    Yoshimitsu, Teruyuki
    Matsukuma, Ken
    Tasaki, Kazuto
    Katsuda, Takahiro
    Terada, Atsumu
    Tsuda, Naotake
    Ushijima, Kimio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (04) : 790 - 801
  • [28] BEVACIZUMAB WITH METRONOMIC ORAL CYCLOPHOSPHAMIDE FOR PATIENTS WITH RECURRENT CERVICAL CANCER
    Isono, R.
    Goto, M.
    Takimoto, Y.
    Ueda, T.
    Inoue, K.
    Ito, K.
    Tsubamoto, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A145 - A146
  • [29] Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer
    Hiroki Nasu
    Shin Nishio
    Jongmyung Park
    Teruyuki Yoshimitsu
    Ken Matsukuma
    Kazuto Tasaki
    Takahiro Katsuda
    Atsumu Terada
    Naotake Tsuda
    Kimio Ushijima
    International Journal of Clinical Oncology, 2022, 27 : 790 - 801
  • [30] Gemcitabine and anthracyclines in platinum-resistant ovarian cancer
    Galligioni, E.
    Arcuri, C.
    Sorio, R.
    Griso, C.
    ANNALS OF ONCOLOGY, 2006, 17 : V195 - V198
12345